Pharmigene, Inc.
7595
Rank in Stocks
#28117
Pharmigene, Inc. operates globally, specializing in the creation, production,... Pharmigene, Inc. operates globally, specializing in the creation, production, and distribution of diagnostic testing solutions. Its offerings include molecular diagnostic tools specifically designed to detect adverse drug reactions, alongside DNA extraction products crucial for diverse applications such as gene expression analysis, clinical molecular diagnostics, human identity verification, forensic investigations, and biomedical research. The firm also provides an array of specialized services, including pharmacogenomics, drug allergy screening, and functional medicine assessments. Beyond its own products, Pharmigene distributes various genomics and genetics equipment and reagents. Complementing these, it offers a comprehensive suite of support solutions, encompassing expert consultation, training programs, analytical software, and technical assistance. Furthermore, the company extends its capabilities through Contract Development and Manufacturing Organization (CDMO) services. Pharmigene, founded in 1994, is headquartered in Taipei, Taiwan.
Share Price
$0.24326598
Last synced: 2026-11-10
Market Cap
$12.28M
Change (1 day)
2.31%
Change (1 year)
-30.83%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Pharmigene, Inc. (7595)
Category
Healthcare
Operating Margin for Pharmigene, Inc. (7595)
Operating Margin as of November 2026 TTM: -23.86%
According to Pharmigene, Inc.'s latest financial reports, its current operating margin (TTM) is -23.86%. At the end of 2025 the company had an operating margin of -27.49%.
Operating Margin history for Pharmigene, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -23.86% | -13.20% |
| 2025 | -27.49% | -60.59% |
| 2024 | -69.75% | 56.39% |
| 2023 | -44.60% | 34.26% |
| 2022 | -33.22% | 88.96% |
| 2021 | -17.58% | 26.47% |
| 2020 | -13.90% | -70.39% |
| 2019 | -46.95% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -100.81% |
DE
|
|
| 19.68% | -100.82% |
DE
|
|
| 13.26% | -100.56% |
JP
|
|
| 17.08% | -100.72% |
CH
|
|
| 14.92% | -100.63% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Pharmigene, Inc.'s operating margin
What is Pharmigene, Inc.'s operating margin?
Pharmigene, Inc.'s operating margin is -23.86%, as of Nov 2026.
What was Pharmigene, Inc.'s operating margin in 2025?
In 2025, Pharmigene, Inc.'s operating margin was -27.49%, compared with -69.75% in 2024.
How has Pharmigene, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Pharmigene, Inc.'s operating margin was highest in 2020 (-13.90%) and lowest in 2024 (-69.75%).
How does Pharmigene, Inc.'s operating margin compare with similar companies?
Pharmigene, Inc.'s operating margin (-23.86%) is lower than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.